Rationale Methamphetamine is a commonly abused drug and dopaminergic neurotoxin. Repeated administration of high doses of methamphetamine induces programmed cell death, suppression of dopamine release, and reduction in locomotor activity. Previous studies have shown that pretreatment with peroxisome proliferator-activated receptor gamma (PPARγ) agonist reduced methamphetamine-induced neurodegeneration. Objectives The purpose of this study was to examine the role of endogenous PPARγ in protecting against methamphetamine toxicity. Methods Adeno-associated virus (AAV) encoding the Cre recombinase gene was unilaterally injected into the left substantia nigra of loxP-PPARγ or control wild-type mice. Animals were treated with high doses of methamphetamine 1 month after viral injection. Behavioral tests were examined using rotarod and rotometer. In vivo voltammetry was used to examine dopamine release/clearance and at 2 months after methamphetamine injection. Results Administration of AAV-Cre selectively removed PPARγ in left nigra in loxP-PPARγ mice but not in the wild-type mice. The loxP-PPARγ/AAV-Cre mice that received methamphetamine showed a significant reduction in time on the rotarod and exhibited increased ipsilateral rotation using a rotometer. The peak of dopamine release induced by local application of KCl and the rate of dopamine clearance were significantly attenuated in the left striatum of loxP-PPARγ/AAV-Cre animals. Tyrosine hydroxylase immunoreactivity was reduced in the left, compared to right, nigra, and dorsal striatum in loxP-PPARγ/AAV-Cre mice receiving high doses of methamphetamine. Conclusion A deficiency in PPARγ increases vulnerability to high doses of methamphetamine. Endogenous PPARγ may play an important role in reducing methamphetamine toxicity in vivo.
Introduction
Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor that forms a complex with the retinoic X receptor and binds to the PPAR response element (PPRE) in the promoter region of specific genes, such as interleukin-1β, IL-6, tumor necrosis factor alpha, catalase, and superoxide dismutase to regulate their expression. PPARγ is also present in cytosol in neuronal cells (Isaac et al. 2006; Xu et al. 2010) and can be translocated to nuclei after injury (Xu et al. 2010) . PPARγ is involved in attenuating neurodegeneration in several neurological diseases, including Parkinson's disease (Dehmer et al. 2004; Schintu et al. 2009 ), Alzheimer's disease (Jiang et al. 2008) , and stroke (Shimazu et al. 2005; Tureyen et al. 2007; Victor et al. 2006; Zhao et al. 2005) as well as methamphetamine (MA)-induced psychomotor sensitization (Maeda et al. 2007) .
MA is a commonly abused drug and dopaminergic neurotoxin. Repeated administration of high doses of MA induces programmed cell death, suppression of dopamine (DA) release, and reduction in tyrosine hydroxylase (TH) immunoreactivity. Some of these presynaptic changes are reversible. Using an in vivo electrochemical measurement, it has been shown that potassium-evoked DA overflow in striatum was reduced 1 week after high-dose MA administration in adult Fisher rats. The evoked DA overflow partially recovered after 1 month and fully recovered by 6 months (Cass and Manning 1999) . These data suggest that high doses of MA can induce a reversible electrochemical dysfunction in dopaminergic neurons.
Recent studies have indicated that PPARγ agonists can modify neurodegeneration in dopaminergic neurons. Chronic treatment with the PPARγ agonists rosiglitazone or piloglitazone attenuated MPTP-mediated motor deficits and loss of TH(+) cells in substantia nigra compacta in mice (Quinn et al. 2008; Schintu et al. 2009 ). Administration of rosiglitazone reduced microglial activation and partially restored dopamine content in MPTP-lesioned animals (Schintu et al. 2009 ). Pretreatment with the PPARγ agonist 15d-PG J2 or ibuprofen reduced the high-dose MA-mediated loss of DAT immunoreactivity and the accumulation of microglial cells in the striatum 3 days after repeated MA injection (Tsuji et al. 2009 ). Taken together, these data suggest that activation of PPARγ reduces neurodegeneration induced by MA or other dopaminergic toxins. The endogenous protective role of PPARγ pathway against dopaminergic toxins, i.e., in the absence of pharmacological agonists, is still not fully clarified, particularly since the agonists used may have actions at other sites.
The purpose of this study was to examine the protective roles of endogenous PPARγ in MA-mediated neurodegeneration using PPARγ-deficient animals. The conventional elimination of PPARγ in knockout mice results in early lethality by embryonic days 10-11 due to placental dysfunction (Barak et al. 1999) . The Cre/loxP system can be used to produce a cell-specific or conditional knockout by deleting a gene of choice in a specific cell type. In this study, we selectively removed PPARγ in the substantia nigra unilaterally by stereotaxic injection of an adeno-associated virus (AAV) encoding the gene for Cre recombinase, which resulted in excision of the PPARγ gene coding sequence flanked by loxP sites (Kaspar et al. 2002; Scammell et al. 2003) . We found that a deficiency of PPARγ in the substantia nigra increases vulnerability to high doses of MA.
Methods

AAV vectors
The generation of the control vector, AAVgreen fluorescent protein (GFP), has been described (Lowery et al. 2009 ). The construction of AAV-GFP/Cre (Cre-GFP fusion protein, referred to as "AAV-Cre" in the current manuscript) has also been described previously (Kaspar et al. 2002) . Viral stocks were prepared using a triple transfection method (Howard et al. 2008; Xiao et al. 1998 ). Both vectors were packaged using pAAV7, the rep/cap plasmid for generating serotype 7 (Gao et al. 2002) . Plasmids used for packaging AAV were generously provided by Dr. Xiao Xiao (UNC, Chapel Hill, NC, USA). Both vectors were purified by CsCl gradient and titered by quantitative PCR using GFP as the target sequence. Viral titers are recorded as viral genome per milliliter.
Animals Homozygous loxP-PPARγ mice (strain name, B6.129-Ppargtm2Rev/J; stock number, 004584) were purchased from Jackson Laboratories and were bred in the animal facility at the NIDA IRP. Control wild-type (WT) mice (C57/BL6) were purchased from CRL laboratories. All protocols and animal care procedures were in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications no. 80-23, revised 1996) . The use of these animals for this study was approved by the Animal Care and Use Committee, NIDA. All animals were genotyped by PCR before viral injection according to previously described methods (He et al. 2003) .
Unilateral AAV injection into substantia nigral region Adult male loxP-PPARγ and WT mice were anesthetized with chloral hydrate (400 mg/kg, i.p.). The animals were placed in a stereotaxic frame (Stoelting), where a 10 μl Hamilton syringe with a 30-gauge needle was used to stereotactically deliver AAV-Cre (2 μl of 5×10 9 viral genomes/μl) at a speed of 0.5 μl/min into left substantia nigral region (coordinates: AP, −3.3 mm; ML, +1.2 mm to bregma and DV 4.2 mm from skull surface according to Paxinos and Franklin's "the Mouse Brain"). The needle remained in the brain for 2 min after the injection then slowly removed. After recovery from anesthesia, animals were housed in their home cages.
Injection of MA or saline At 1 month after viral injection, animals were treated with (+) MA (10 mg/kg, ×4 doses, each dose 2 h apart) or saline (every 2 h, 4 doses, s.c.). This high dose of MA is required to induce neural toxicity in rodents (Grace et al. 2010; Jayanthi et al. 2005; Zhu et al. 2006) and has been used to examine protection against MA-mediated neural degeneration in mice (Chou et al. 2008; Wang et al. 2001) . Core body temperature was monitored by a mouse rectal probe (YSI, Yellow Springs, OH, USA).
Rotarod treadmill test Animals received 3 days of training (twice daily) before MA or saline administration. Each animal was placed in the respective lane on treadmill, 13.75 in above the testing platform. For training, the rod was rotated at 5 rpm initially and then accelerated to 10 rpm. The test was performed again at 10 rpm on days 3, 10, and 42 after MA or saline injection. Cutoff time for each test was 360 s. Each animal was tested five times per day. The two longest endurance times (E Time ) on the rotating rod in five trials were averaged and used for analysis.
Rotation At 45 days after MA or saline injection, animals were tested for rotational behavior in response to subcutaneous (+) MA injections (2.5 mg/kg, s.c.) in an automated rotometer (Accuscan Instruments, Columbus, OH, USA). Each animal was placed in a cylindrical test chamber for 90 min. The highest consecutive clockwise and counterclockwise rotations over 60 min were used for analysis.
Western blot analysis The frozen striatal tissues were homogenized in radioimmunoprecipitation assay buffer containing 50 mM Tris-HCl, pH 7.4, 1% NP40, 0.25% deoxycholic acid, 150 mM sodium chloride, 1 mM EDTA, and1% protease inhibitor (Roche, Germany). Lysates were cleared by centrifugation (14,000×g at 4°C for 5 min), and the total protein concentration in each sample was determined by DCA assay using bovine serum albumin (BSA) as a standard curve. Lysates were separated by NuPAGE® Novex Bis-Tris gels 4-12% gel from Invitrogen, and the proteins were transferred to Immobilon-FL membranes (Millipore, Billerica, MA, USA). After preblocking in Odyssey blocking buffer from Li-Cor for overnight at 4°C, the membranes were incubated with the primary antibody rabbit anti-actin (1:2,500, Sigma, St. Louis, MO, USA) and mouse antityrosine hydroxylase (TH) (1:5,000, Millipore) at room temperature for 2 h, then incubated for 90 min in goat anti-rabbit IR-700 nm, goat-anti-mouse IR-800 nm secondary antibodies (1:2,500, Li-Cor, Lincoln, NE, USA). The membranes were scanned using an Odyssey infrared imager (Li-Cor, Lincoln, NE, USA). Immunoblots were quantified with ImageJ.
In vivo voltammetry KCl-evoked DA release in striatum was measured at >2 months after MA or saline injection. Animals were anesthetized using urethane (1.25 g/kg, i.p.).
In vivo chronoamperometric measurements of extracellular dopamine (DA) concentration were performed as previously described (Zhou et al. 1996) . The recordings were taken at rates of 10 Hz continuously using Nafion-coated carbon fiber working electrodes (tip030 μm; SF1A, Quanteon, Lexington, Kentucky) and a microcomputer-controlled apparatus (FAST system, Quanteon). The release of DA was measured by changes of extracellular DA concentration after microinjection of KCl into the striatal parenchyma. KCl (70 mM) in osmolarity-balanced saline (79 mM NaCl and 2 mM CaCl 2 ) was locally applied through a micropipette at 100-200 nl range. The concentration and volume of KCl solution in the pipette have been previously reported to induce depolarization and release of dopamine at dopaminergic nerve terminals in vivo (Hoffman et al. 1998; Wang et al. 2003) . The working electrode and the micropipette were mounted together with sticky wax; tips were separated by 150 μm. The electrode/pipette assembly was lowered into striatum (AP, 0-0.5 mm, M/L 2.0 mm relative to bregma and 1.5-3.5 mm below the dura). Local application of KCl from the micropipette was performed by pressure ejection using a pneumatic pump (BH2, Medical System). The ejected volume was monitored by recording the change in the fluid meniscus in the pipette before and after ejection using a dissection microscope.
Immunohistochemistry Mice were perfused transcardially with saline followed by 4% paraformaldehyde in 0.1 M phosphate-buffered (PB) saline. Brains were stored in 18% sucrose and sectioned coronally (25 μm) using a Leica cryostat. Free-floating brain sections were rinsed three times with PB for 10 min and incubated for 1 h with blocking solution (4% BSA and 0.3% Triton X-100 in PB). Brains sections (25 μm in thickness) were immunolabeled using primary anti-TH polyclonal antibody (Millipore, Temecula, CA, USA; 1:500) for 2 days or rabbit anti-PPARγ (Santa Cruz biotechnology, Santa Cruz, CA, USA; 1:50) antibody overnight at 4°C. For immunofluorescence, molecular probes Alexa 568 secondary antibodies (Invitrogen, Carlsbad, CA, USA; 1:500) were included for 3 days for TH or overnight at 4°C for PPARγ. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI; Molecular Probes, 1:1,000). Control sections were incubated without primary antibody. Confocal analysis was performed using a Nikon D-ECLIPSE 80i microscope and EZ-C1 3.90 software.
Quantification of TH immunoreactivity in striatum The bound primary antibody primary anti-tyrosine hydroxylase (TH) polyclonal antibody (Millipore, Temecula, CA, USA; 1:500) was visualized using the infrared-labeled secondary antibody (goat anti-rabbit IRDye800, Rockland Immunochemicals Inc.) 1:500 in 4% BSA and 0.3% Triton X-100 in PB for 1 h. Sections were rinsed three times with PB and mounted on gelatin ⁄chrome-alum coated slides and coverslipped. TH immunoreactivity in brain sections were scanned and quantified by a Li-Cor Odyssey scanner. TH signal from cerebral cortex was used as a background and subtracted from striatum TH signal. Densitometry was carried out in sections with an identified anterior commissure (between AP, +1.10 and 0.14mm to bregma), and signals were averaged.
TH cell count in midbrain An ABC method was used and sections were incubated in biotinylated horse anti-rabbit IgG (1:200; Vector Laboratories, Burlingame, CA, USA) for 1 h, followed by incubation for 1 h with avidin-biotin-horseradish peroxidase complex as described previously (Chou et al. 2008) . Staining was developed with 2,3′-diaminobenzidine tetrahydrochloride (0.5 mg/mL). Sections were then mounted on gelatin ⁄chrome-alum coated slides and coverslipped. For TH-positive cell counts histological images were acquired using an Infinity 3 camera, NIKON 80i microscope and QCapture Pro 5.0 software, and TH-positive cell counts were done with NIS elements software (Nikon) and personnel blinded as to treatment. TH-positive cells were averaged from sections between AP, −3.16 and −3.64 mm to bregma as described previously (Chou et al. 2008) .
RNA isolation and standard PCR for detection of recombination Approximately 2 weeks after injection, animals were euthanized and brains removed. Using a cryostat, brains were coronally sectioned from posterior to anterior from 1 mm posterior to the site of injection, and a 2-mm diameter tissue punch (∼2 mm depth) was made from each hemisphere and combined. Total RNA was isolated from the combined hemispheres using Rneasy Lipid Extraction Kit (Qiagen) and reverse transcribed using iScript cDNA synthesis kit (Biorad). Using established reaction conditions and primers (Zhao et al. 2009 ), PCR was performed to detect wild-type (700 bp) and recombinant PPARγ (300 and 400 bp).
Quantitative PCR Using cDNA prepared as described above, PPARγ and ubiquitin-conjugating enzyme E2I (Ube2i, reference gene) mRNA levels were measured by real-time quantitative PCR (TaqManTM chemistry, Roche) and analyzed with a CFX96 thermal cycler (Bio-Rad). PPARγ and UBE2i primers and probes were designed using Real Time Design (Bioresearch Technologies, Novato, CA, USA). UBE2i was used as a housekeeping gene based on previous work (Kobayashi et al. 2004 ). Real-time PCR results were calculated using the 2 −ΔΔCT method (Schmittgen and Livak 2008) . Briefly, the threshold cycle (Ct) of PPARγ was normalized to the Ct of the reference gene Ube2i for each sample, which was used to determine fold changes in PPARγ mRNA expression compared to wild-type animals injected with AAV-GFP.
Primer and probe sequences are as follows:
Results
AAV-Cre and recombination of loxP-PPARγ
A total of 12 loxP-PPARγ and 12 wild-type mice received intranigral administration of AAV-Cre (serotype 7) or AAV-GFP. Recombination by AAV-Cre was confirmed by standard PCR of cDNA prepared from tissue punches of midbrain at 2 weeks after viral delivery. Only loxP-PPARγ animals that received AAV-Cre were positive for recombination (Fig. 1a) . Quantitative PCR analysis of the cDNA from the midbrain showed a 50% reduction [p00.0019, F (3, 23) 0 7.123, one-way ANOVA+Newman-Keuls test] in PPARγ mRNA levels for loxP-PPARγ animals receiving AAV-Cre, compared to all other groups (Fig. 1b) . The efficiency of AAV serotype 7 transduction was examined 2 weeks after local administration of AAV-Cre in three WT mice. AAV transduced about 56±4% of TH cells in the nigra based on colocalization of TH immunoreactivity and GFP fluorescence ( Fig. 1c-e) . Overall, these results demonstrate that AAV-GFP/Cre successfully transduced dopaminergic neurons and caused a reduction in PPARγ expression in the nigra region. At 1 month after AAV injection, the GFP fluorescence from the GFP/Cre fusion of AAV-Cre was expressed in TH and non-TH cells in the left nigra region (Fig. 2) . Using confocal microscopy, we found that GFP fluorescence colocalized with the nuclear marker DAPI in the TH neurons (Fig. 2d) . No GFP fluorescence was found in the striatum or in the contralateral hemisphere. These data suggest that Cre-GFP fusion protein was produced in the dopaminergic and non-dopaminergic cells at the site of injection and localized to the nucleus. Immunolabeling cells in the substantia nigra for PPARγ showed a decrease of PPARγ-immunoreactivity in GFP/Cre-positive cells of loxP-PPAR, but not wild-type, animals (Fig. 3) .
TH immunoreactivity in striatum WT and loxP-PPARγ mice were treated with AAV-Cre unilaterally in the left nigra area. Striatal tissue in the left hemisphere was collected for Western analysis at 2 days after MA or saline administration. MA treatment, compared to saline treatment, significantly reduced striatal TH/actin immunoreactivity in loxP-PPARγ/AAV-Cre and WT/AAVCre mice (p<0.05, F 1, 33 022.349, two-way ANOVA+post hoc Newman-Keuls test, Fig. 4a and b) . Our data suggest that high doses of MA can acutely induce neurodegeneration in striatum. No difference was found in striatal TH activity between loxP-PPARg/AAV-Cre and WT/AAV-Cre mice receiving MA. These data suggest that MA induces a similar neurodegeneration in these mice at 2 days after MA treatment.
Rotarod
A total of 34 mice (15 loxP-PPARγ and 19 WT mice) were treated with AAV-Cre unilaterally in the left nigra area. Animals received 3 days of training before MA or saline administration. One WT mouse was removed from this behavioral study during the training period. One month after viral injection, animals were treated with MA (n015) or saline (n018). Rotorod tests, at 10 rpm, were taken on days 3, 10, and 42 after injection of MA or saline. Saline injection did not alter the endurance time (E Time ) in loxP-PPARγ/AAV-Cre and WT/AAV-Cre mice (Fig. 5 ). In contrast, high doses of MA significantly reduced E Time up to 42 days after injection (F 1, 84 0102.337, p<0.001, three-way ANOVA). There is a statistically significant interaction between the administration of MA and treatment of AAV-Cre in loxP-PPARγ animals (F 1, 84 05.286, p00.024, three-way ANOVA, Fig. 5 ), suggesting that unilaterally deleting PPARγ potentiates MA-mediated behavioral deficits. Post hoc Newman-Keuls analysis indicates a significant reduction of rotarod performance in loxP-PPARγ mice treated with AAV-Cre and MA, compared to WT mice treated with AAV-Cre and MA (p00.012).
Rotation
A two-way ANOVA was used to analyze rotational behavior in 34 mice at 45 days after receiving saline or MA (10 mg/ kg×4, s.c.). Rotation was recorded every 2 min for 90 min after administration of a low dose of MA (2.5 mg/kg, s.c.). Animals developed both ipsilateral and contralateral rotation after injection. No difference was found in the contralateral rotation between loxP-PPARγ/AAV-Cre and WT/AAV-Cre mice (F 1, 29 00.002, p00.963, Fig. 6b ) or treatment with Real-time PCR of cDNA revealed that only loxP-PPARγ animals receiving AAV-Cre showed a significant reduction in PPARγ (∼50%). Data were normalized to reference gene, Ube2i. *p<0.05, **p<0.01, One-way ANOVA, Newman-Keuls post hoc analysis compared to WT/AAV-GFP group. c-e Tyrosine hydroxylase immunoreactivity (c), GFP fluorescence (d), and merged image (e) at 2 weeks after local administration of AAV-GFP/Cre injection in nigra region. GFP was detected in both TH-positive and TH-negative cells saline or high-dose MA (F 1, 29 00.002, p00.963). In contrast, there is a significant difference in ipsilateral rotation between loxP-PPARγ/AAV-Cre and WT/AAV-Cre mice (F 1, 29 012.366, p00.01). There is also a significant interaction between use of MA and treatment with AAV-Cre in loxP-PPARγ mice (F 1, 29 05.288, p00.029). Post hoc Newman-Keuls test indicates that treatment with high dose of MA significantly increased ipsilateral rotation in loxP-PPARγ/AAV-Cre animals, as compared to WT/AAV-Cre controls (p<0.05, Fig. 6a ).
KCl-induced DA release in striatum KCl-evoked DA release in striatum was examined using in vivo voltammetry in eight loxP-PPARγ/AAV-Cre and eight WT/AAV-Cre mice at 2 months after high dose of MA Fig. 2 The GFP/Cre fusion protein of AAV-Cre is expressed in dopaminergic and nondopaminergic cells in nigra at 1 month after AAV-Cre injection. TH immunoreactivity (A1 and A2, low and high magnification) and GFP fluorescence (B1 and B2) were found in the nigra area at the site of injection. GFP fluorescence was co-expressed in TH (B1 and B2) and non-TH cells in nigra (C1 and C2, merged). Confocal photomicrographs indicate that GFP/Cre is present in the nuclei of TH-containing cells in substantia nigra pars compacta (SNpc), ipsilateral to AAV-Cre injection (D). No GFP fluorescence was observed in the TH cells in the contralateral SNpc (E). Scale bars: A1, B1, C1 100 μm; A2, B2, C2, D, E 20 μm injection. KCl-evoked DA release was recorded in 150 striatal sites between 1.5 and 3.5 mm below the brain surface. Of these, 80 sites were taken from the striatum ipsilateral (L) to the AAV-Cre injection, while 70 sites were recorded in the contralateral (R) striatum. Average dose of KCl ejected from micropipette was 176.9±7.5 nl per site. Local application of KCl resulted in the release of dopamine in all striatal sites contralateral to AAV-Cre injection in both WT/AAV-Cre and loxP-PPARγ/AAV-Cre mice. Typical extracellular dopamine tracings from left and right striatum are shown in Fig. 7a and B.
Previous voltammetric studies have shown a dose-response relationship between the peak of extracellular DA level and log dose of applied DA through micropipette in rat striatum (Sabeti et al. 2002a, b) . In this study, the amplitude of DA release was thus normalized by comparing to the log volume (in nanoliters) of KCl used. A similar approach has been used in our previous papers (Wang et al. 2003 ). We There is a further reduction of E Time in loxP-PPARγ/AAV-Cre, compared to WT/AAV-Cre, mice. *p<0.05, three-way ANOVA+Newman-Keuls test Fig. 3 Injection of AAV-Cre reduces PPARγ expression in the nigra region in floxed PPARγ mice. a Both PPARγ (red) and GFP (green) were expressed in the same cells (arrows) in nigra area at 2 months after injection of AAV-Cre to a wild-type mouse. b PPARγ immunoreactivity was suppressed in cells expressed GFP (arrows) after injection of AAV-Cre to a floxed PPARγ mouse. Scale bar050 μm first examined the averaged KCl-evoked DA release in L or R striatum from all WT/AAV-Cre and loxP-PPARγ/AAVCre mice pretreated with high-dose MA. There was a significant reduction in KCl-evoked DA release in the L striatum in the KO, as compared to R striatum in KO, L or R striatum in WT/AAV-Cre mice (Fig. 8a, p<0 .001, F 3, 146 0 7.713; p<0.001, post hoc Newman-Keuls test). No difference was found between the R and the L striata in WT/AAVCre mice. Previous studies have shown that KCl-evoked DA partially recovered after 1 month and fully recovered by 6 months after high doses of MA administration in adult Fisher rats (Cass and Manning 1999) . Similarly, no difference was found in the contralateral striatum between the animals treated with saline or MA at 2 months after injection. The rate of DA clearance (nanomolars per second) after KCl application was calculated between T20 and T60 as described previously (Cass and Manning 1999) . There was a significant reduction of DA clearance in the striatum ipsilateral to the AAV-Cre injection in loxP-PPARγ mice after MA treatment (F 3, 137 03.826, p00.011, one-way ANOVA, Fig. 8b ).
KCl-evoked DA release and clearance were further analyzed topographically, every 0.5 mm, from 1.5 to 3.5 mm below the brain surface (Fig. 9) . The release of dopamine, elicited by KCl in the L striatum of loxP-PPARγ/AAV-Cre mice, was significantly reduced compared to the L striatum in WT/AAV-Cre mice (p<0.05, Two-way ANOVA+Newman-Keuls test, Fig. 9a ). Most of these differences are found in dorsal striatum (Fig. 9a) . No difference was found in the R striatum between WT/AAV-Cre and loxP-PPARγ/AAV-Cre mice (Fig. 9b) . These data suggest that deficiency in PPARγ expression attenuates KCl-induced release of dopamine in the striatum. The reduction of DA clearance was mainly manifested in the left dorsal striatum in loxP-PPARγ/AAVCre (Fig. 9c, p<0 .05, two-way ANOVA). No difference was found in the right striatum between WT/AAV-Cre and loxP-PPARγ/AAV-Cre mice (Fig. 9d) .
TH immmunoreactivity
Mice receiving unilateral AAV-Cre were killed after voltammetric recording or 2 months after MA or saline injection. AAV-Cre administration did not alter TH fiber or cell density in striatum or nigra in ipsilateral, compared to the contralateral, hemisphere in three WT/AAV-Cre or in three loxP-PPARγ/AAV-Cre mice receiving saline injection. High dose of MA treatment did not alter striatal TH immunoreactivity in WT/AAV-Cre mice (Fig. 10a) ; however, reduced TH immunoreactivity, mainly in the dorsal region, in loxP-PPARγ/AAV-Cre mice (Fig. 10b) was found. Striatal TH immunoreactivity of brain slices with an identified anterior commissure was further quantified using ImageJ. TH fiber density in left striatum, normalized to the TH activity in WT mice treated with saline, was significantly reduced in loxP-PPARγ/AAV-Cre (n05), compared to WT/AAV-Cre (n06), mice after MA injection (Fig. 10g, p00.044, t test) . In the midbrain area, administration of MA or saline did not affect TH immunoreactivity in the left nigra in WT/AAV-Cre mice (Figs. 10c and e) . In contrast, treatment with MA (Fig. 10d) , but not saline (Fig. 10f) , induced a prominent reduction in TH cell density in the left nigra area in loxP-PPARγ/AAV-Cre mice. The density of TH cells in midbrain slice between −3.16 and −3.64 mm from bregma was counted. TH cell count, ipsilateral to the AAV-Cre injection side (left), was normalized to that on the contralateral side (right) in each brain slice. A significantly reduction in TH cell count in the left nigra (Fig. 10h, p00 .001, t test), but not in the left VTA (Fig. 10i, p00 .980, t test), was found in loxP-PPARγ/ AAV-Cre (n07), compared to WT/AAV-Cre (n05), mice receiving MA injection. No significant reduction in DAPI activity was found in left or right nigra region in these mice (p00.185, F 3, 16 01.815, one-way ANOVA).
Discussion
In this study, we show that the GFP/Cre fusion protein is present in nigra, both in TH and non-TH cells 1 month after AAV-Cre injection. We found that administration of AAVCre caused reduction in PPARγ expression, detected by qRT-PCR, in nigra of loxP-PPARγ, but not WT/AAV-Cre, mice. Expression of GFP/Cre fusion protein using AAV serotype 7 in the midbrain was not limited to TH cells but did transduce approximately 56% of TH-immunoreactive cells in substantia nigra pars compacta. PCR analysis confirmed that recombination of the PPARγ gene occurred and caused a 50% reduction in PPARγ expression in the midbrain. Using immunostaining, we found a decrease in PPARγ immunoreactivity in GFP/Cre-positive cells of loxP-PPAR but not wild-type animals after AAV-Cre infection. These data suggest that administration of AAV-Cre provides a long-term reduction in PPARγ expression in the substantia nigra of adult floxed animals. Our data support other reports that AAV serotype 7 transduces rodent neurons (Howard et al. 2008; Taymans et al. 2007) . Taken together, these data suggest that local injection with AAV-Cre can deliver Cre recombinase, promote recombination, and cause a reduction of PPARγ expression in the TH neurons in nigra in the loxP-PPARγ mice.
It has been shown that activation of PPARγ by the exogenous agonist rosiglitazone prevents MPTP-mediated motor impairment and neurodegeneration in nigrostriatal dopaminergic neurons (Schintu et al. 2009) . In this study, we examined the protective roles of endogenous PPARγ against dopaminergic toxicity induced by high doses of MA. We suppressed the endogenous PPARγ unilaterally in nigra by injection of AAV-Cre to loxP-PPARγ mice to elicit rotational behavior, similar to that in the unilaterally 6-OHDA-lesion rodent model of Parkinson's disease. The imbalance in dopaminergic innervation after unilateral lesioning can be identified by rotation after injection of apomorphine or amphetamine (Ungerstedt and Arbuthnott 1970) as well by rotarod without drug challenge (Fang et al. 2010; Monville et al. 2006; Rozas and Labandeira Garcia 1997) .
We found that administration of saline did not alter rotarod or rotational activity in WT/AAV-Cre or loxP-PPARγ/AAVCre mice. Similarly, KCl-evoked DA release or DA clearance in striatum was not altered in these animals (data not shown). These data suggest that the selective unilateral depletion of PPARγ alone does not alter DA release and clearance in striatum or locomotor function in the animals.
Both in vivo and in vitro studies have shown that high doses of MA acutely induces dysfunction in dopaminergic neurons, i.e., increasing apopototic markers, reducing tyrosine hydroxylase or DAT expression, and suppressing DA release (Chou et al. 2008; Shen et al. 2011 ). We also found that MA reduced TH immunoreactivity in striatum in both loxP-PPARγ and wild-type mice receiving AAV-Cre. Our data suggest that high doses of MA can acutely induce neurodegeneration in striatum. Similar to rotarod behavioral responses on day 3 after MA administration, no difference in striatal TH activity was found between lox-P PPARγ/ AAV-Cre and WT/AAV-Cre mice receiving MA. These data suggest that MA induces a similar neurodegeneration in these mice acutely after MA treatment.
A recent study has indicated that pretreatment with ibuprofen or the selective PPARγ agonist 15d-PG attenuates the reduction of striatal DAT expression after repeated MA injection (4 mg/kg×4) in mice (Tsuji et al. 2009 ), suggesting that activation of PPARγ by exogenous ligands attenuates MA toxicity. In this study, we found that unilaterally reducing PPARγ expression potentiated the MA-induced reduction in rotorod retention time, increased ipsilateral rotation after lowdose MA injection, and lowered KCl-evoked DA release and clearance in the knockout side striatum at 1-2 months after MA injection. Taken together, our data suggest that suppression of PPARγ potentiates MA-mediated toxicity in dopaminergic neurons.
Administration of amphetamine analogs causes ipsilateral rotation in unilaterally 6-OHDA-lesioned rats due to differential increase of dopaminergic activity on the intact side. There is a correlation between amphetamine-induced ipsilateral rotation and the depletion of dopamine in the nigra (Hudson et al. 1993) . Unlike 6-OHDA-lesioned rats, which produce continuously and consistently ipsilateral rotation after amphetamine administration, the floxed PPARγ and WT mice used in current study developed both ipsilateral and contralateral rotations after administration of a low dose of MA. Such a difference may be due to the following: (a) mice with C57/B6 background are more active in response to drug stimulation, and/or (b) pretreatment with high doses of MA did not induce a near-complete lesioning in striatum compared to 6-OHDA lesioning. Although these animals developed contra and ipsilateral rotation based on differential DA innervation between ipsilateral and contra-lateral hemispheres, there was still a bias on direction of rotation. For example, no difference was found in contralateral rotation between WT/AAV-Cre and loxP-PPARγ/AAV-Cre mice, pretreated with either saline or high-dose MA. A significant increase in ipsilateral rotation was noted only in loxP-PPARγ/AAV-Cre pretreated with high dose of MA. The increase in ipsilateral rotation suggests that high-dose MA enhances degeneration of DA neurons unilaterally in loxP-PPARγ/ AAV-Cre mice.
The deficiency in DA function in loxP-PPARγ/AAV-Cre mice at 2 months after MA treatment is further supported by in vivo electrochemical data. We used high-speed chronoamperometry to examine the time course of KCl-evoked DA release and clearance in striatum. The dose of KCl applied locally was between 7 and 14×10 -11 mol (70 mM×100-200 nl) per site. The dose, concentration, and volume of the KCl solution have been previously reported to induce depolarization and release of dopamine at dopaminergic nerve terminals in vivo (Hoffman et al. 1998; Wang et al. 2003) . We found that local administration of KCl induced DA release equally in L and R striatum of WT/AAV-Cre mice and in the non-viral injected striatum of loxP-PPARγ/ AAV-Cre mice. Previous studies have demonstrated that the suppression of KCl-mediated DA release is reversible in 1-6 months after high doses of MA administration in adult Fisher rats (Cass and Manning 1999) , suggesting a spontaneous recovery of DA release function. We also found no difference in DA release between MA and saline-treated WT/AAV-Cre mice at 2 months after injection. In contrast to saline injection, KCl-evoked DA release and the rate of DA clearance were significantly attenuated in the L striatum in loxP-PPARγ/AAV-Cre at 2 months after MA treatment. These electrochemical data suggest that deficiency in PPARγ expression in nigra potentiates or prolongs MA-mediated neurodegeneration in striatum. In agreement with changes in distribution of TH immunoreactivity, the There is a significant reduction of KCl-evoked DA release in the L striatum in KO, as compared to R striatum in KO, and to L or R striata in WT/ AAV-Cre mice (p<0.001). b The rate of DA clearance (nM/s) after KCl application was calculated between T20 and T60. There is a significant reduction in DA clearance in the striatum ipsilateral to the AAV-Cre injection in loxP-PPARγ mice after MA treatment (p00.011, one-way ANOVA)
suppression of KCl-evoked DA release and clearance in the loxP-PPARγ/AAV-Cre mice was mainly seen in the dorsal striatum. Less difference between loxP-PPARγ/AAV-Cre and WT/AAV-Cre was found in the ventral striatum, which may be attributed to its topographic innervation of dopaminergic neurons from VTA. We have previously demonstrated that MA binge treatment (10 mg/kg×4) does not lead to loss of dopaminergic neurons in SNpc (Luo et al. 2010 ). There is a significant reduction of TH immunoreactivity in striatum at 3 days after MA treatment (Chou et al. 2008) , suggesting that MA produced mainly DA terminal lesions. In this study, we found that deficiency in PPARγ expression can lead to a chronic reduction of TH cell bodies in ipsilateral nigra after binge MA treatment, suggesting that suppression PPARγ expression reduces protection in nigra after MA treatment.
Several reports have supported that PPARγ exerts protective effects through anti-inflammation. PPARγ agonists inhibited production of monocyte inflammatory cytokines (Jiang et al. 1998) . Treatment with the PPARγ agonist pioglitazone reduced MPTP-mediated microglia activation and neurotoxicity in nigral dopaminergic neurons (Dehmer et al. 2004 ). On the other hand, high dose of MA induced inflammation (Asanuma et al. 2004) . It is thus possible that deficiency in endogenous PPARγ may indirectly facilitate MA-mediated inflammatory reactions, which may result in regional neurodegeneration in mice with unilateral depletion of PPARγ. Further studies are needed to determine the role of inflammation in MA-mediated midbrain toxicity in these animals.
In summary, our behavioral, histological, and electrochemical data suggest that deficiency in endogenous PPARγ does not alter dopaminergic function in the absence of injury, but enhances neurodegeneration after exposure to high-dose MA. It has been reported that endogenous PPARγ expression is suppressed in certain clinical disorders (Hindle et al. 2009; Yamamoto-Furusho et al. 2011 ) and can be inhibited by various pharmacological agents. It may be that a deficiency in endogenous PPARγ in these or other conditions increases vulnerability to MA insults and that Fig. 9 Topographic distribution of a, b KCl-evoked DA release and (c, d) clearance in the striatum in loxP-PPARγ/AAV-Cre (red tracing) and WT/AAV-Cre (black tracing) at 2 months after high-dose MA administration. a The release of dopamine elicited by KCl in the L striatum of mice was significantly reduced, compared to the L striatum in WT/AAV-Cre mice (p<0.05, two-way ANOVA+Newman-Keuls test). Most of these differences were in dorsal striatum. b No difference was found in the R striatum between WT/AAV-Cre and loxP-PPARγ/ AAV-Cre mice. c A reduction in DA clearance was seen in the L striatum in loxP-PPARγ/ AAV-Cre mice (p<0.05, twoway ANOVA). d No difference in clearance was found in the contralateral striatum between WT/AAV-Cre and loxP-PPARγ/AAV-Cre mice endogenous PPARγ may play an important role in reducing MA toxicity in vivo. Moreover, one recent study has indicated that conditionally knocking out PPARγ increases ischemic brain damage (Zhao et al. 2009 ). These data supports the idea that PPARγ is important for minimizing brain injury and may be a target for pharmacotherapy in neurodegeneration.
Acknowledgment This study was supported by NIDA IRP. We thank Dr. Barry Hoffer for his critical suggestions. Fig. 10 Reduction of TH immunoreactivity in loxP-PPARγ/AAV-Cre mice at 2 months after MA injection. a, c In a wild-type animal, unilateral injection AAV-Cre to the left nigra area did not alter TH immunoreactivity at 2 months after MA injection in a striatum and c nigra, ipsilateral to AAV-Cre injection. In contrast, in a loxP-PPARγ mouse (b, d), MA treatment reduced TH immunoreactivity in the b left striatum and d left nigra region (arrow), ipsilateral to AAV-Cre injection. Administration of saline did not alter TH activity in nigra region in e WT and f loxP-PPARγ mice. Scale bar: a, b 1 mm. g TH fiber density in left striatum at the level of anterior commissure, normalized to striatal TH density in WT mice treated with saline, was significantly reduced in loxP-PPARγ/AAV-Cre, compared to WT/AAV-Cre, mice after MA injection (p00.044, t test). h, i TH cell counts, ipsilateral to the AAV-Cre injection side (left), were normalized to that in contralateral side (right) in each brain slice. A significant reduction in TH cell counts in left nigra (h, p00.001, t test), but not in left VTA (i, p00.980, t test), was found in loxP-PPARγ/AAV-Cre, compared to WT/AAVCre mice receiving MA injection
